Targets › GYRAA
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout May 2027.
Open in Phaseline: the race on GYRAA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Boston University | Levofloxacin DNA gyrase inhibitor; Topoisomerase IV inhibitor | GYRAA | Phase 2 | Tuberculosis, Multidrug-Resistant | May 2027 |
Tuberculosis, Multidrug-Resistant (1)
small molecule (1)
Boston University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.